“…In the treatment of primary brain tumors, the platinum doses usually used are much lower than those in lung or ovarian cancer, 20 mg/m 2 per cycle instead of 70-100 mg/m 2 per cycle (Stewart et al, 1984;Follezou et al, 1989;Mahaley et al, 1989;Newton et al, 1989;Lord and Coleman, 1991;Kiu et al, 1995;Frenay et al, 2000Frenay et al, , 2005Gilbert et al, 2000;Zustovich et al, 2007). In carboplatin, two chlorine groups are substituted by cyclobutane dicarboxylate, resulting in a lower reactivity with DNA, although the same products are formed.…”